Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566878 · ClinicalTrials.gov registry record
Pompe Lactation Sub-Registry
A clinical trial of Pompe Disease and Glycogen Storage Disease, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 2
- Enrollment target
- 2
- Study locations
NCT00566878: Completed study of Pompe Disease and Glycogen Storage Disease, sponsored by Genzyme, a Sanofi Company.
NCT00566878 is a study of Pompe Disease and Glycogen Storage Disease that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 2 participants, below the 232-participant average among 14 other Pompe Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00566878, a study of Pompe Disease and Glycogen Storage Disease, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective is to determine if alglucosidase alfa is present in breast milk from mothers with Pompe Disease being treated with alglucosidase alfa and to measure breast milk production and composition in women with Pompe Disease who receive alglucosidase alfa.
Conditions Studied
Interventions
- BIOLOGICAL alglucosidase alfa
Study Locations (2)
Massachusetts
- Registry participation is worldwide. Facilities not yet active may enroll upon identification of a patient - Cambridge
Michigan
- - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-03-31 |
| Est. Completion | 2024-02-09 |
What the finished NCT00566878 record still lists
NCT00566878 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 232-participant average among 14 other Pompe Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Pompe Disease appearing as the primary indexed condition, and to 1 intervention - of which alglucosidase alfa is the first listed.
NCT00566878 reports a single indexed study location in Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT00566878 about?
NCT00566878 is a clinical study titled "Pompe Lactation Sub-Registry". The objective is to determine if alglucosidase alfa is present in breast milk from mothers with Pompe Disease being treated with alglucosidase alfa and to measure breast milk production and composition in women with Pompe Disease who receive alglucosidase alfa.
What is the current status of trial NCT00566878?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2012-03-31. Estimated completion is 2024-02-09.
What conditions does trial NCT00566878 study?
This clinical trial studies the following conditions: Pompe Disease, Glycogen Storage Disease.
What interventions are being tested in trial NCT00566878?
The interventions under investigation include: alglucosidase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00566878?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00566878 being conducted?
This trial has 2 study locations across Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pompe Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00566878's enrollment target sits among peer trials
2 15th of 14 the lowest of 14 other Pompe Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pompe Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
RECRUITING · Phase 2
-
Cognitive and Neurological Pathologies in Pompe Disease
RECRUITING
-
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
RECRUITING
-
Pompe Disease Registry Protocol
RECRUITING
-
A Global Prospective Observational Registry of Patients With Pompe Disease
RECRUITING
-
Avalglucosidase Alfa Pregnancy Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI